Acta Pol Pharm 59:235–236PubMed Sztanke K (2004) Synthesis of new derivatives SGC-CBP30 of 8-aryl-3-phenyl-6,7-dihydro-4H-imidazo[2, 1-c][1,2,4]triazin-4-one. Acta Pol Pharm 61:373–377PubMed Sztanke K, Fidecka S, Kedzierska E, Karczmarzyk Z, Pihlaja K, Matosiuk D (2005) Antinociceptive activity of new imidazolidine carbonyl derivatives. Part 4.

Synthesis and pharmacological activity of 8-aryl-3,4-dioxo-2H,8H-6,7-dihydroimidazo[2,1-c] [1,2,4]triazines. Eur J Med Chem 40:127–134PubMedCrossRef Tully WR, Gardner CR, Gillespie RJ, Westwood R (1991) 2-(Oxadiazolyl)- and 2-(thiazolyl)imidazo[1,2-a]pyrimidines as agonists and inverse agonists at benzodiazepine receptors. J Med Chem 34:2060–2067PubMedCrossRef Turner JV, Ward AD, Freeman CG (1978) The mutagenic screening of fourteen imidazo compounds using a modified Ames’ test. Mutat Res 57:135–139PubMedCrossRef Vidal A, Ferrándiz ML, Ubeda A, Acero-Alarcón A, Sepulveda-Arques J, Alcaraz MJ (2001) Effect of imidazo[1,2-a]pyrimidine derivatives on leukocyte function. Inflamm Res 50:317–320PubMedCrossRef Vogel GH, Vogel W (1997) Drug discovery and evaluation.

Pharmacological assays. Springer, BerlinCrossRef”
“Introduction Tricyclic phenothiazines attract considerable attention because of their significant biological activities and interesting chemical features. Classical phenothiazines with aminoalkyl substituents at the nitrogen atom are the source of valuable drugs exhibiting neuroleptic, Cilengitide in vitro antihistaminic, antitussive, and antiemetic activities (Gupta and Kumar, 1988). The selleck structure modifications of these compounds were carried out by introduction of new substituents, mainly at the thiazine nitrogen atom, and

substitution of one or two benzene rings with homoaromatic and heteroaromatic rings. The modifications with azine rings lead to formation of azaphenothiazines. New phenothiazines can contain not only the tricyclic ring system but also tetra and pentacyclic ones with up to four additional nitrogen atoms in the aromatic rings (Silberg et al., 2006; Pluta et al., 2009, 2011). Such modifications can change potency and type of activities of the basic structures. Recent reports describe very promising anticancer, antibacterial, and anti-inflammatory activities, reversal of multidrug resistance and a potential benefit in treatment of Alzheimer’s, Creutzfeldt-Jakob’s and AIDS-associated diseases for the modified phenothiazines (Motohashi et al., 2000, 2006; Dasgupta et al., 2008; Sadandam et al., 2009; Aaron et al., 2009; Tandon et al., 2009; Pluta et al., 2011). Our GSK1120212 solubility dmso strategy for modification of the phenothiazine structure is based on the introduction of two pyridine rings instead of the benzene ones to form dipyrido[1,4]thiazines. Among ten theoretically possible dipyridothiazines types only four have been known before introduction of our research strategy, i.e., 1,6- (Maki, 1957; Takahashi and Maki, 1958a, b; Rodig et al.